Search / 39 results found

from
to
  • Updated

THURSDAY, Jan. 6, 2022 (HealthDay News) -- The U.S. Centers for Disease Control and Prevention on Wednesday endorsed the emergency use of the Pfizer booster shots for children ages 12 to 17 years, expanding protection to adolescents and teens as students return to classes and the highly contagious omicron variant surges across the country.

  • Updated

TUESDAY, Jan. 4, 2022 (HealthDay News) -- The U.S. Centers for Disease Control and Prevention on Tuesday backed the emergency use approval of the Pfizer COVID-19 booster shot for high-risk children between the ages of 5 and 11 years, along with shortening the time period between a second dose and a booster shot from six months to five months.

TUESDAY, Jan. 4, 2022 (HealthDay News) -- The U.S. Centers for Disease Control and Prevention on Tuesday backed the emergency use approval of Pfizer's booster shot for high-risk kids between the ages of 5 and 11, along with shortening the time period between a second dose and a booster shot from six months to five months.

  • Updated

THURSDAY, Dec. 23, 2021 (HealthDay News) -- Many Americans now have two oral antiviral pills that can be taken at home to treat a fresh case of COVID-19. The U.S. Food and Drug Administration on Thursday approved the emergency use of the molnupiravir pill from Merck for the treatment of mild-to-moderate COVID-19 in people who have just tested positive.